title: Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.
abstract: BACKGROUND
  The efficacy of platinum- and ifosfamide-based chemotherapy regimens as salvage treatment in metastatic breast cancer (MBC) has not yet been sufficiently evaluated.
  
  
  METHODS
  Patients with MBC treated with cisplatin plus ifosfamide with (PEI) and without (PI) etoposide in our clinic between 04/2005 and 04/2014 were retrospectively analyzed.
  
  
  RESULTS
  A total of 20 patients (median four prior chemotherapies) treated with PEI/PI were identified, out of whom 18 were evaluable for objective response. Treatment with PEI/PI resulted in one complete remission, nine partial remissions and two cases of stable disease. The median (range) progression-free survival was 4 (0-18) months and median overall survival from therapy initiation was 8.5 (0-50) months. PEI/PI therapy caused grade 3/4 toxicities (mainly hematological) in 80% of patients.
  
  
  CONCLUSIONS
  PEI/PI is an adequate salvage treatment for patients with MBC but cannot be generally recommended due to toxicity. However, comparison with platinum monotherapy trials suggests that PEI/PI might be a more effective treatment for patients with triple-negative breast cancer.
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany piet.habbel@charite.de.
authors.forename: Piet
authors.initials: P
authors.lastname: Habbel
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Annika
authors.initials: A
authors.lastname: Kurreck
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Carsten-Oliver
authors.initials: CO
authors.lastname: Schulz
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Anne Constanze
authors.initials: AC
authors.lastname: Regierer
authors.affiliation: Department of Radiation Oncology, Charité Campus Virchow, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: David
authors.initials: D
authors.lastname: Kaul
authors.affiliation: Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany.
authors.forename: Christian Wilfried
authors.initials: CW
authors.lastname: Scholz
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Neumann
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Kurt
authors.initials: K
authors.lastname: Possinger
authors.affiliation: Department of Hematology and Oncology, Charité Campus Mitte, Charité-University Medicine Berlin, Berlin, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Eucker
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide
keywords: Metastatic breast cancer; chemotherapy; etoposide; ifosfamide; platinum